What Would It Take to Get Peptides on the Shelf?
The panel voted to let licensed specialty pharmacies compound six peptides despite FDA scientists’ safety concerns and limited human evidence.
- On last week, a Food and Drug Administration advisory panel recommended loosening compounding restrictions for six unapproved peptides, including BPC-157 and TB-500, despite safety concerns raised by agency scientists.
- Health and Human Services Secretary Robert F. Kennedy Jr. appointed eight new members to the Pharmaceutical Compounding Advisory Committee, six of whom have industry ties, to address the unregulated gray market where peptides are already widely obtained.
- Agency scientists raised concerns about insufficient published human data and potential safety risks, warning that compounding authorization does not meet the rigorous standards required for FDA-approved medicines.
- If approved, patients would need prescriptions, though Scott Brunner, who leads the Alliance for Pharmacy Compounding, warned that sourcing ingredients could "it's going to create some chaos" and take up to nine months.
- The FDA leadership must now decide whether to authorize production, with legal experts suggesting officials may leverage expedited pathways like the "Category One list" to bypass traditional rulemaking and accelerate availability.
13 Articles
13 Articles
Unregulated Peptides Are ‘Truly The Wild West’ Right Now — And The FDA’s Next Decision Could Have Severe Consequences
The panel’s recommendations could shape the future of popular peptides, but some doctors say the review process itself deserves closer scrutiny.
Peptides: The FDA opens a ‘Pandora’s box’
“America is about to go over a peptide cliff,” said Tom Bartlett in The Atlantic. An FDA advisory panel voted last month to recommend that six unproven peptides be added to the list of custom drugs that so-called compounding pharmacies can sell. Peptides are chains of amino acids that tell cells to regulate biological processes; some peptides, including insulin and GLP-1s, are FDA-approved medicines. But pharmacies were banned in 2023 from dispe…
Access to regenerative peptides likely to increase
It was widely reported last week that the FDA’s Pharmacy Compounding Advisory Committee recommended six new peptides for inclusion on the list of medications that may be produced by licensed compounding pharmacies under federal law. This made headlines for a…
Coverage Details
Bias Distribution
- 64% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
